AMPH Amphastar Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMPH

Price (delayed)

$37.57

Market cap

$1.8B

P/E Ratio

19.98

Dividend/share

N/A

EPS

$1.88

Enterprise value

$1.75B

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active ...

Highlights
The net income has grown by 47% YoY and by 18% from the previous quarter
The EPS has grown by 45% YoY and by 19% from the previous quarter
The stock's P/E is 84% less than its 5-year quarterly average of 125.6 but 10% more than its last 4 quarters average of 18.1
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Peers: MRNS RGLS SCYX ASMB

Key stats

What are the main financial stats of AMPH
Market
Shares outstanding
47.9M
Market cap
$1.8B
Enterprise value
$1.75B
Valuations
Price to earnings (P/E)
19.98
Price to book (P/B)
3.43
Price to sales (P/S)
3.66
EV/EBIT
14.96
EV/EBITDA
12.12
EV/Sales
3.5
Earnings
Revenue
$498.99M
EBIT
$116.71M
EBITDA
$144.03M
Free cash flow
$65.57M
Per share
EPS
$1.88
Free cash flow per share
$1.35
Book value per share
$10.94
Revenue per share
$10.28
TBVPS
$14.51
Balance sheet
Total assets
$741.99M
Total liabilities
$213.33M
Debt
$102.58M
Equity
$528.66M
Working capital
$283.46M
Liquidity
Debt to equity
0.19
Current ratio
3.99
Quick ratio
2.81
Net debt/EBITDA
-0.37
Margins
EBITDA margin
28.9%
Gross margin
49.9%
Net margin
18.3%
Operating margin
21.5%
Efficiency
Return on assets
12.6%
Return on equity
18.2%
Return on invested capital
22.2%
Return on capital employed
18%
Return on sales
23.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
1.79%
1 week
3.53%
1 month
15.46%
1 year
5.03%
YTD
34.08%
QTD
34.08%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$498.99M
Gross profit
$248.86M
Operating income
$107.5M
Net income
$91.39M
Gross margin
49.9%
Net margin
18.3%
The operating income has surged by 54% year-on-year and by 14% since the previous quarter
The net income has grown by 47% YoY and by 18% from the previous quarter
AMPH's operating margin is up by 34% year-on-year and by 11% since the previous quarter
AMPH's net margin is up by 29% year-on-year and by 15% since the previous quarter

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
P/E
19.98
P/B
3.43
P/S
3.66
EV/EBIT
14.96
EV/EBITDA
12.12
EV/Sales
3.5
The stock's P/E is 84% less than its 5-year quarterly average of 125.6 but 10% more than its last 4 quarters average of 18.1
The EPS has grown by 45% YoY and by 19% from the previous quarter
The price to book (P/B) is 37% higher than the 5-year quarterly average of 2.5 and 11% higher than the last 4 quarters average of 3.1
Amphastar Pharmaceuticals's equity has increased by 19% YoY and by 4.7% from the previous quarter
AMPH's price to sales (P/S) is 26% more than its 5-year quarterly average of 2.9 and 14% more than its last 4 quarters average of 3.2
Amphastar Pharmaceuticals's revenue has increased by 14% YoY and by 2.9% QoQ

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The company's return on assets rose by 34% YoY and by 16% QoQ
The ROIC is up by 26% year-on-year and by 12% since the previous quarter
The ROE has grown by 25% YoY and by 14% from the previous quarter
The ROS has grown by 23% YoY and by 11% from the previous quarter

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
Amphastar Pharmaceuticals's quick ratio has increased by 34% YoY and by 9% QoQ
Amphastar Pharmaceuticals's current ratio has increased by 30% YoY and by 6% from the previous quarter
AMPH's debt is 81% smaller than its equity
Amphastar Pharmaceuticals's equity has increased by 19% YoY and by 4.7% from the previous quarter
Amphastar Pharmaceuticals's debt to equity has decreased by 17% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.